



Prostate Cancer Progression

Guest Editor:

Dr. Isabel Heidegger-Pircher

Department of Urology, Medical
University Innsbruck, 6020
Innsbruck, Austria

Deadline for manuscript
submissions:

closed (25 October 2023)

Message from the Guest Editor

Prostate cancer is one of the most prevalent malignancies. While most cases are diagnosed at a localized stage, a considerable number of patients with intermediate or high-risk localized, locally advanced or metastatic cancer die from the disease each year. Although therapeutic advances have been introduced in the field of metastatic PC, androgen deprivation therapy remains the leading therapeutic backbone for metastatic PC. However, most patients develop castration resistance. The exact mechanisms driving the progression from androgen-dependent PC to castration-resistant prostate cancer are not completely understood. The treatment landscape of metastatic CRPC has substantially improved due to the availability of different agents. However, fast tumor progression, cross-resistance, the use of these substances in earlier stages of the disease, and patient-related factors should be taken into account when assessing which is the optimal treatment sequencing in the setting of mCRPC. This Issue aims, to better understand the biological mechanisms of tumor progression and, to elucidate recent clinical developments in the treatment of both localized and metastatic disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)